💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Talazoparib

CHEMBL3137320 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
380.4 g/mol
LogP
2.3
Phase
4

Talazoparib is a potent PARP1/2 inhibitor that traps the PARP-DNA complex on damaged DNA, preventing repair and causing irreparable double-strand breaks and cell death specifically in tumor cells with homologous recombination deficiency (HRD) such as BRCA1/2-mutated cancers. It is approved for the treatment of HER2-negative locally advanced or metastatic breast cancer in patients with germline BRCA mutations, and is under investigation in other BRCA-associated tumors. Its high PARP-trapping potency provides superior cytotoxicity in BRCA-deficient cells compared to earlier PARP inhibitors.

น้ำหนักโมเลกุล

380.4000 g/mol

LogP

2.30

TPSA

84.20 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

Melanoma Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Lymphoma Breast Cancer Prostate Cancer Colorectal Cancer Leukemia

กลไกการออกฤทธิ์

Inhibits poly(ADP-ribose) polymerase (PARP) enzymes involved in DNA single-strand break repair, exploiting homologous recombination deficiency in cancer cells to cause synthetic lethality.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Inhibits poly(ADP-ribose) polymerase (PARP) enzymes involved in DNA single-strand break repair, exploiting homologous recombination deficiency in cancer cells to cause synthetic lethality.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1

                

                

                
                

                    
InChI

                    
InChI=1S/C19H14F2N6O/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28/h2-8,15-16,24H,1H3,(H,26,28)/t15-,16-/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C19H14F2N6O

                    

                    
                    

                        
HBD / HBA

                        
2 / 7

                    

                    
                    

                        
พันธะที่หมุนได้

                        
2

                    

                    
                    
                    

                        
อะตอมหนัก

                        
28

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
คำถามที่พบบ่อย

                

                    
                    

                        
                        

                            
Talazoparib is a potent PARP1/2 inhibitor that traps the PARP-DNA complex on damaged DNA, preventing repair and causing irreparable double-strand breaks and cell death specifically in tumor cells with homologous recombination deficiency (HRD) such as BRCA1/2-mutated cancers. It is approved for the treatment of HER2-negative locally advanced or metastatic breast cancer in patients with germline BRCA mutations, and is under investigation in other BRCA-associated tumors. Its high PARP-trapping potency provides superior cytotoxicity in BRCA-deficient cells compared to earlier PARP inhibitors.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits poly(ADP-ribose) polymerase (PARP) enzymes involved in DNA single-strand break repair, exploiting homologous recombination deficiency in cancer cells to cause synthetic lethality.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Talazoparib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL3137320.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 135565082.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
ข้อจำกัดความรับผิดชอบทางการแพทย์

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.